A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant. The study is open to adults with type 1 or type 2 diabetes and will last about 50 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes

NCT02806960

Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

TERMINATED PHASE1

Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia

NCT01556594

Hypoglycemia

COMPLETED PHASE2

A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults

NCT02778113

Healthy

COMPLETED PHASE1

Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults

NCT01994746

Diabetes Mellitus, Type 1

COMPLETED PHASE3

Evaluate the Immunogenicity of a Novel Glucagon Formulation

NCT01959334

Drug-specific Antibodies Diabetes Mellitus

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nasal Glucagon (NG) - Treatment 1

One dose of 3 milligram (mg) NG administered in one of four study periods.

Group Type EXPERIMENTAL

Nasal Glucagon

Intervention Type DRUG

Administered intranasally.

NG - Treatment 2

Two NG doses, 3 mg each dose, administered 15 minutes apart, in the same nostril, in one of four study periods.

Group Type EXPERIMENTAL

Nasal Glucagon

Intervention Type DRUG

Administered intranasally.

NG - Treatment 3

Two NG doses, 3 mg each dose, administered 15 minutes apart, in opposite nostrils, in one of four study periods.

Group Type EXPERIMENTAL

Nasal Glucagon

Intervention Type DRUG

Administered intranasally.

NG - Treatment 4

Two NG doses, 3 mg each dose, administered one immediately after the other, in opposite nostrils, in one of four study periods.

Group Type EXPERIMENTAL

Nasal Glucagon

Intervention Type DRUG

Administered intranasally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nasal Glucagon

Administered intranasally.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AMG504-1 LY900018

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female with a history of Type 1 or Type 2 insulin-using diabetes of at least 1 year duration (basal only, basal bolus, meal-time only, or twice a day pre-mixed insulin)
* A female participant must meet one of the following criteria:

* Participant is of childbearing potential and agrees to use one of the accepted contraceptive regimens from at least 28 days prior to the first administration of the study drug, during the study and for at least 30 days after the last dose of the study drug
* Participant is of non-childbearing potential, defined as surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state (at least 1 year without menses)
* Participant with a body mass index (BMI) greater than or equal to 18.50 kilograms per square meter (kg/m²) and below 35.00 kg/m²
* Light-, non- or ex-smokers
* In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the Investigator is a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations

Exclusion Criteria

* Females who are pregnant, actively attempting to get pregnant, or are lactating
* History of significant hypersensitivity to glucagon or any related products as well as severe hypersensitivity reactions (such as angioedema) to any drugs
* Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
* Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases
* Known presence of rare hereditary problems of galactose and /or lactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
* Presence of clinically significant findings on nasal examination or bilateral anterior rhinoscopy, such as structural abnormalities, nasal polyps, marked septal deviation, nasal tumors
* Nasal surgery in the previous 28 days before Day 1 of this study
* Daily use of a systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of this study
* Any other concomitant maintenance therapy that would influence the outcome of the trial or compromise the safety of the participant, at the discretion of the Investigator and the Sponsor, in the previous 28 days before Day 1 of this study
* Significant history of drug dependency or alcohol abuse
* Any clinically significant illness in the previous 28 days before Day 1 of this study
* Any history of tuberculosis and/or prophylaxis for tuberculosis
* Positive urine screening of alcohol and/or drugs of abuse
* Positive results to human immunodeficiency virus (HIV) Antigen/Antibody (Ag/Ab) Combo, Hepatitis B surface Antigen (HBsAG (B) (hepatitis B)) or anti-Hepatitis C Virus (HCV (C)) tests
* Concurrent participation or intention of participating in another clinical trial during this study
* Participants who took an Investigational Product (in another clinical trial) in the previous 28 days before Day 1 of this study or who have already participated in this clinical study
* Participants who donated 50 milliliters (mL) or more of blood in the previous 28 days before Day 1 of this study
* Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before Day 1 of this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No